Is Option B+ the Best Choice?

HIV & AIDS, Infectious Diseases,
Journal Articles

Is Option B+ the Best Choice?

By: Scott Kellerman, Jonathan S. Jay, Jonathan D. Quick
Publication: The Lancet 381 (9874) (April 13, 2013): 1273.

Letter to the Editor 

Anna Coutsoudis and colleagues worry that international organisations have too hastily endorsed a strategy to provide lifelong triple antiretroviral therapy (ART), irrespective of CD4 count, to pregnant women with HIV in high-burden countries. This strategy for preventing mother-to-child transmission is called Option B+. It was pioneered in Malawi,2 where the lack of CD4 testing resources impeded effective rollout of WHO Options A or B. Without timely CD4 results, both WHO regimens risk withholding therapy from women who need it. Other countries share this limitation. Yet even where all three regimens are feasible, Option B+ might be best.